Literature update: 18 November 2026
Keywords: trigeminal neuralgia; botulinum toxin type A; mandibular pain; facial sensory anatomy; intraoral treatment; aesthetic medicine.
Clinical context
Trigeminal neuralgia (TN) is characterized by recurrent, usually unilateral attacks of severe electric shock-like facial pain, often triggered by innocuous stimulation. Brushing teeth, washing the face, speaking and eating may precipitate attacks. Some patients also have continuous pain between paroxysms. Classical, idiopathic and secondary TN describe aetiology; the presence of continuous pain is a separate clinical descriptor. These distinctions matter because dental disease, painful post-traumatic trigeminal neuropathy and myofascial pain can produce overlapping symptoms but represent different study populations. [1]
Pain location and trigger location also need separate description. A tooth or gingival contact may provoke a neuralgic attack without demonstrating primary dental pathology, while dental and neuralgic disorders can coexist. Conversely, a superficial trigger field does not necessarily identify the initiating lesion. In classical TN, neurovascular compression with morphological nerve changes is part of the diagnostic framework. Improvement after peripheral treatment is therefore evidence of an analgesic effect, rather than proof that the disease originates in the injected tissue. [1,2]
Carbamazepine and oxcarbazepine remain first-choice medicines in European guidance. Botulinum toxin type A (BoNT-A) is an additional option in selected patients, with a weak European Academy of Neurology recommendation based on very-low-quality evidence. Royal College of Surgeons guidance also recognizes uncertainty about dosing and administration. TN remains outside the indications listed in the current UK Botox product information. These statements describe its position within existing treatment pathways; they do not negate the clinical signal reported in controlled studies. [2–4]
For aesthetic clinicians, the practical question is how published TN treatment regions relate to familiar landmarks: the depressor anguli oris (DAO), mentalis, masseter, parotid region, mandibular border, platysma, temple, forehead and lateral orbital area. The relevant distinction is the tissue reached. A superficial injection over a muscle, an intramuscular injection and an injection into an underlying gland are anatomically adjacent interventions with different physiological targets. This review brings those published observations together for clinical presentation and discussion.
Scope of the evidence
The review draws on targeted searches of PubMed-indexed records, accessible primary articles, guidelines and official trial information. The main inventory was assembled on 6 November 2026, with a targeted update on 18 November. A 2024 comprehensive review provided a discovery set for earlier publications, which were checked against primary sources where accessible. The author reports identifying 45 human clinical reports and recording whether full text, abstracts or bibliographic information were available. The separate evidence inventory was not supplied for editorial verification. [5]
Studies are grouped by design, diagnosis and route. Product-specific units and randomized denominators are retained. Possible overlapping cohorts are not added into a unique-patient total, and no new meta-analysis is presented. Research on migraine, dystonia, myofascial pain, sialorrhoea and aesthetics is discussed for its relevance to interpretation. This is a structured narrative synthesis rather than an exhaustive systematic review.
Controlled clinical evidence
The established placebo-controlled evidence consists of four trials involving 182 randomized participants. All reported an analgesic signal, but their formulations, doses and treatment distributions differed. The main approaches were intradermal, subcutaneous or submucosal treatment of painful or trigger territories. One trial included an additional masseter component for mandibular involvement. Table 1 summarizes these studies; their combined sample describes the placebo-controlled evidence, rather than every comparative study in the literature. [6–9]
Wu and colleagues randomized 42 patients to Lanzhou-produced BoNT-A or saline. At 12 weeks, at least 50% pain reduction was reported in 68.2% of the active group and 15.0% of controls. Zhang and colleagues randomized 84 patients to 25 or 75 product units of Lanzhou toxin or placebo. At eight weeks, responder proportions were 70.4%, 86.2% and 32.1%, respectively. The absence of a statistically significant difference between active doses does not establish dose equivalence. [6,9]
Zúñiga and colleagues studied 36 participants using subcutaneous onabotulinumtoxinA, with an ipsilateral masseter adjunct for V3 involvement. The three-month pain score favoured active treatment; the two-month comparison did not reach conventional statistical significance. Shehata and colleagues studied 20 participants and reported a greater 12-week reduction in pain with active treatment. Facial asymmetry occurred in four of ten treated patients, illustrating how visible motor effects can compromise masking in an otherwise blinded trial. [7,8]
These trials support short-term efficacy but leave several anatomical questions unanswered. They did not directly compare a cosmetic lower-face pattern with a sensory trigger-zone pattern, isolate the masseter contribution, or establish an optimal protocol for exclusively mandibular TN. Follow-up was principally eight to twelve weeks. Accordingly, the controlled findings are more secure for short-term pain improvement than for long-term durability, repeated-treatment performance or the independent value of particular facial muscles. [6–9]
A separate open-label randomized study in 2017 compared one treatment with two treatments two weeks apart. One hundred patients were randomized and 81 completed follow-up. Most outcomes were similar, while reported benefit lasted longer in the single-treatment group. Unequal cumulative exposure, attrition and the absence of placebo complicate interpretation. The 2025 comparison cited in reference 11 could not be independently verified and is not used to draw conclusions. [10,11]
Observational evidence and repeated treatment
The observational literature expands the clinical experience beyond the small placebo trials. Li and colleagues followed 88 patients for up to 14 months, while a later retrospective series included 152 patients. Such studies describe response trajectories, recurrence and retreatment in routine care. Their interpretation is affected by spontaneous fluctuations, changes in medication, loss to follow-up and selection of patients who continue treatment. Possible overlap among reports from the same institutions also complicates pooled patient counts. [12,13]
Asan and colleagues reported 53 patients, including 31 with multiple-sclerosis-related TN and 22 with primary TN; both groups contained responders. Tereshko and colleagues studied 40 patients with and without concomitant continuous pain and found improvement in both phenotypes without a significant between-group difference. These observations broaden the clinical discussion, but small nonrandomized subgroup comparisons cannot establish equivalent efficacy across aetiologies or show that a particular phenotype benefits from a different treatment map. [14,15]
Xu and colleagues retrospectively evaluated 30 patients in 2025. Pain improved at four weeks, while selected repeat recipients had smaller pain-score changes after later courses than after their first treatment. This does not establish neutralizing-antibody resistance: disease evolution, selection and treatment history provide alternative explanations. Santos and colleagues described four V3 patients treated repeatedly over a mean follow-up exceeding six years. Their experience demonstrates prolonged use in selected patients, while concomitant medication and inconsistent numerical reporting limit estimates of durability. [16,17]
A consistent interpretative issue is the distinction between duration after one treatment and benefit maintained through repeated treatment. Reports describing improvement over a year or longer may include recurrence, additional injections and medication adjustments. Similarly, a responder defined by pain intensity is not automatically a responder for attack frequency, oral function or medication reduction. These endpoints should remain distinct when comparing studies or presenting headline success rates. [10,16,17]
Age-focused cohorts extend the published experience but also illustrate the limits of subgroup interpretation. Liu and colleagues compared 14 patients aged at least 80 years with 29 patients younger than 60. Both groups improved at one month and each had two reported adverse events. The nonrandomized, 43-patient comparison supports feasibility in selected older patients, but is too small to establish equivalent safety across ages. Differences in background medication and patient selection remain relevant when these results are compared with younger trial populations. [18]
Hosseini and colleagues reported three women treated with incobotulinumtoxinA after inadequate improvement with oral treatment. Pain frequency, severity and duration reportedly decreased. This small series adds formulation-specific clinical experience, but does not provide a controlled estimate of efficacy or establish a medication-sparing effect. It is particularly relevant when reviewing incobotulinumtoxinA separately from onabotulinumtoxinA and the Lanzhou preparation used in the larger randomized trials. [19]
Mandibular and oral treatment territories
Lower-lip and chin symptoms, lower gingival triggers and pain perceived in mandibular teeth can all occur within a V3 presentation, but they do not identify one interchangeable peripheral target. The mental region is particularly relevant because it overlaps the surface landmarks used for mentalis and lower-face aesthetic treatment. Its cutaneous and mucosal sensory territory should be distinguished from the deeper dental pathways of the inferior alveolar nerve. Superficial lower-lip or chin coverage does not establish coverage of all mandibular dental branches. [20]
Nvabazam and Judi reported 20 patients treated intraorally near the mental foramen using abobotulinumtoxinA. Nineteen responded during the first year, but ten experienced recurrence and retreatment; one developed lower-lip weakness. The uncontrolled design and discontinuation of background medicines make single-treatment durability difficult to estimate. Pearl and colleagues subsequently described two mandibular cases treated in the mental region, including one associated with multiple sclerosis. Together, these reports provide direct clinical observations for that region without defining a universal V3 protocol. [21,22]
Masseter treatment has a small but identifiable place in the TN literature. It appeared as an adjunct in Zúñiga’s controlled protocol, rather than as a separately tested intervention. Wu and colleagues described a patient with lower gingival TN who reportedly failed submucosal treatment and improved after masseter-directed toxin, with benefit lasting approximately five months. This sequential case supports discussion of the masseter as a possible contributor, but cannot determine whether the effect arose from muscle relaxation, sensory modulation, local spread or treatment sequencing. [7,23]
A 2025 case by Jang combined superficial incobotulinumtoxinA with ultrasound-guided bilateral masseter treatment in a patient with V2/V3 symptoms. Improvement was reported, but the combined approach prevents attribution to either component. The report’s ultrasound findings do not establish a validated marker for selecting a TN target. Clinically, this literature is most useful when neuralgic paroxysms are distinguished from coexisting clenching-related or myofascial pain, so that an improvement in one pain component is not automatically attributed to another. [24]
Upper-lip, infraorbital and upper gingival symptoms belong to a different anatomical discussion, usually involving V2. Radlberger and Leis described additional submucosal treatment of a persistent upper-canine trigger after superficial therapy. Fida and colleagues reported a right V2 case treated intradermally, with pain improvement at two weeks and benefit lasting approximately 4.5 months. These cases illustrate the importance of documenting skin and oral triggers separately. They do not establish that an infraorbital foramen must be entered to obtain an analgesic effect. [25–27]
Anatomical studies help explain why facial and dental treatment fields are related but not identical. Infraorbital terminal branches reach the upper lip, lateral nose and lower eyelid, while superior alveolar dental branches follow intraosseous pathways. Treating a superficial upper-lip field therefore cannot be described as directly treating every maxillary dental branch. Nevertheless, an oral or cutaneous trigger can modulate the same clinical pain presentation, so anatomical separation does not imply that a superficial intervention cannot relieve pain perceived in a tooth. [27,28]
How aesthetic treatment regions relate to the evidence
The overlap with aesthetic practice is substantial at the level of surface anatomy. The DAO and mentalis regions lie close to lower-lip and chin sensory fields; the masseter and temple provide familiar landmarks within the lateral face; and the upper lip and infraorbital region overlap common V2 symptom locations. However, a muscle name describes a motor structure, while a trigeminal territory describes sensory innervation. Published TN studies are therefore most clearly interpreted by recording both the region and the tissue plane. [27,29,30]
Motor innervation adds another useful distinction. DAO and mentalis are muscles of facial expression supplied by the facial nerve, whereas their surrounding sensory territories involve trigeminal branches. A primary DAO dissection identified lower buccal and marginal mandibular facial-nerve contributions. The motor buccal branches of VII should not be confused with the sensory long buccal branch of V3. Thus, a change in smile mechanics after lower-face toxin treatment cannot itself demonstrate modulation of the relevant trigeminal sensory pathway. [31]
Yoshida’s 2021 mixed-diagnosis study illustrates this distinction. Of 28 TN patients, 16 received subcutaneous or submucosal trigger-zone treatment for V3 symptoms and 12 underwent a guided sphenopalatine approach for V2 symptoms. DAO, mentalis and platysma injections were described in the separate oromandibular dystonia group. The paper consequently provides experience with several facial muscles and sensory approaches, but those observations cannot all be assigned to the TN cohort. [29]
The jawline and Nefertiti pattern also cross sensory boundaries. The mandibular angle and lower periauricular skin receive cervical plexus contributions, including the great auricular and transverse cervical nerves. A surface pattern along the mandibular border is therefore not a complete map of V3. Nefertiti and microbotox studies describe aesthetic changes in the lower face and neck; their outcomes help characterize regional treatment effects but do not measure neuralgic attacks or dental trigger responses. [30,32–34]
The forehead, lateral orbital region and temple require the same separation of surface location and target tissue. Forehead sensation is predominantly V1, while lateral facial and temporal boundaries involve adjacent sensory territories. Frontalis, orbicularis oculi and temporalis treatment also alter motor function. PREEMPT provides strong evidence for a defined chronic-migraine programme that includes head and neck muscles, but its population and endpoints differ from TN. It cannot establish that treating those regions relieves remote V2 or V3 attacks. [1,35]
A 2026 randomized aesthetic study by Munoz-Lora and colleagues compared four DAO/platysma treatment distributions in 80 participants. Greater treatment extent was associated with greater lifting and persistence of tissue displacement, alongside more perceived adverse effects in the most extensive group at 90 days. This is relevant to the discussion of broader regional exposure, but the measured benefit was aesthetic. The study does not determine whether broader muscular coverage produces greater analgesia in TN. [36]
Thus, familiar aesthetic landmarks can organize a clinical description of the face, while the published analgesic evidence remains linked to specific sensory fields, routes and populations. Table 2 relates these regions to their existing evidence. This distinction allows the anatomical overlap to be discussed constructively without treating every established aesthetic indication as an established neuralgia indication.
The parotid and preauricular region
Pain around the ear or over the parotid does not by itself establish a glandular mechanism. Part of the preauricular region is supplied by the auriculotemporal nerve, whereas lower auricular and mandibular-angle skin has substantial cervical supply. Superficial treatment over the parotid region and intraparotid treatment consequently address different anatomical compartments. Their evidence should be presented separately even when the surface entry region appears similar. [30,32]
The principal controlled evidence for gland injection concerns salivary secretion. SIAXI randomized 184 adults with neurological sialorrhoea to incobotulinumtoxinA or placebo delivered to the parotid and submandibular glands. Salivary outcomes improved with the higher studied dose; dry mouth and dysphagia were among the treatment-related effects. This establishes a salivary application, but provides no direct estimate of TN pain relief in a patient with normal salivary function. [37]
Intraparotid toxin has also been reported for first-bite syndrome, a distinct parotid pain condition associated with the first bites of a meal. In Ghosh and Mirza’s five-patient postsurgical series, three patients reported significant improvement, one moderate improvement and one no improvement at four months. Complete resolution was not reported. These observations are relevant when interpreting meal-related preauricular pain, but no controlled intraparotid TN study was identified in this review. [38]
Deeper approaches and biological interpretation
Türk Börü and colleagues followed 27 patients after a deeper maxillary/mandibular approach. The reported responder proportion rose from 74.1% at two months to 88.9% at six months, and 44% were pain-free at six months. Patients were retreated when pain recurred. These results describe a treatment course, not six-month efficacy from a single exposure in every patient. The absence of a comparator also means that the series cannot establish superiority over superficial administration, despite its encouraging response proportions. [39]
Sphenopalatine approaches represent a separate route within the published literature. Crespi’s pilot treated ten patients, with nine included in the efficacy analysis; its primary attack-frequency endpoint was negative despite a pain-intensity signal. Yoshida described computer-guided treatment for selected V2 cases. In Thepsoparn’s 2024 prospective cohort, 13 analysed patients improved on pain and attack-frequency measures over 60 days, while ten developed hemifacial palsy and one diplopia, resolving within three months. This complication profile belongs to that deep approach and should not be transferred directly to superficial protocols. [40–42]
A 2025 coronoid V3 case combined Masport with local anaesthetic and steroid interventions, limiting attribution. A 2026 perineural infraorbital report concerned post-traumatic trigeminal neuropathic pain, rather than classical TN. Mechanistic evidence also remains distinct: a 2026 mouse infraorbital-nerve injury study reported reduced pain-like behaviour with altered CGRP-ERK-NaV1.7 signalling. It supports sensory modulation as a biological explanation beyond muscle relaxation, but does not demonstrate the mechanism or anatomical reach of BoNT-A in human classical TN. [43–45]
Danysz and colleagues added a 2026 rat infraorbital-nerve constriction study examining dose, treatment location and duration. Subcutaneous incobotulinumtoxinA reduced mechanical allodynia, with predominantly local effects and benefit persisting up to 56 days. This directly informs the biological discussion of regional treatment: location can matter even when the proposed action includes sensory modulation. Translation remains uncertain because an experimental nerve-injury model differs from human classical TN and does not validate a clinical facial injection map. [46]
Interpretation of the current literature
The literature supports a short-term analgesic effect of localized BoNT-A treatment, with the clearest controlled evidence arising from superficial painful or trigger territories. Oral and mental-region reports are directly relevant to mandibular and dental presentations. Masseter and deeper approaches extend the clinical observations, but their independent contributions are less well resolved. Aesthetic and salivary studies provide additional anatomical and physiological context, while answering different clinical questions. [6–9,22,37]
The main limitations are small controlled samples, varied products, inconsistent outcome definitions, short follow-up and potential unblinding through facial weakness. Observational reports add longer experience but are vulnerable to selection and concomitant treatment effects. Product units should remain attached to their formulation; a vial size should not be confused with the administered dose. Similarly, a treatment described as successful after repeated courses should not be presented as a durable response to one injection. [4,10,16]
Official Danish and Stanford sources describe continuing TN toxin research. Those records indicate an active research field, but do not supply published results validating a comprehensive aesthetic facial pattern. For a clinical presentation, the useful synthesis is the relationship between the observed outcome, the treated sensory region and the actual tissue plane. Keeping those details together explains both the promise of BoNT-A and the limits of extrapolating across different facial applications. [47,48]
Conclusion
BoNT-A has a clinically relevant short-term analgesic signal in TN, supported by small placebo-controlled trials and a broader observational literature. The lower face, oral mucosa and selected peripheral territories have direct published treatment experience. Familiar aesthetic regions overlap these territories, but skin, muscle, nerve-adjacent tissue and salivary gland interventions should retain their separate identities when the evidence is presented. Current data support anatomical interpretation of reported approaches; they do not establish one comprehensive facial injection pattern for every V2 or V3 presentation.
Table 1. Established placebo-controlled TN trials
| Study | Population | Reported intervention | Principal finding | Interpretation |
|---|---|---|---|---|
| Wu 2012 [6] | 42 randomized: 22 active, 20 placebo | Lanzhou toxin, 75 product units; intradermal/submucosal painful territory | At 12 weeks, pain responders: 68.2% versus 15.0% | Small study; facial asymmetry; short follow-up |
| Zúñiga 2013 [7] | 36 randomized: 20 active, 16 placebo | OnabotulinumtoxinA, 50 units subcutaneously; additional 10 units into the ipsilateral masseter for V3 cases | Three-month VAS: 4.75 versus 6.94, p = 0.01 | Masseter contribution was not separately randomized |
| Shehata 2013 [8] | 20 randomized: 10 per group | OnabotulinumtoxinA, 40–60 units; principally subcutaneous symptom/trigger fields | Twelve-week VAS reduction: 6.5 versus 0.3 | Facial asymmetry in 4/10 active patients; potential unblinding |
| Zhang 2014 [9] | 84 randomized: 27, 29 and 28 in three arms | Lanzhou toxin, 25 or 75 product units versus saline; intradermal/submucosal | Eight-week pain responders: 70.4%, 86.2% and 32.1% | No significant active-dose difference; equivalence not established |
TN, trigeminal neuralgia; V3, mandibular division; VAS, visual analogue scale. Study exposures are reported in formulation-specific units, which are not interchangeable. Responders in Wu and Zhang refer to at least 50% reduction in pain intensity. The total of 182 is the randomized population of these four placebo-controlled trials.
Table 2. Facial regions and their relationship to the published evidence
| Region | Tissue and sensory relationship | Published evidence and interpretation |
|---|---|---|
| DAO and mentalis region | Superficial lower-lip/chin field versus facial-expression muscle | Mental-region reports exist. DAO/mentalis muscle treatment in Yoshida belonged to the dystonia cohort. [21,22,29] |
| Masseter | Overlying sensory field versus masticatory muscle | Adjunct in one controlled protocol, plus case reports; its independent TN contribution remains unresolved. [7,23,24] |
| Temporalis and temple | Temporal skin and underlying muscle have different innervation | Migraine and muscular-pain evidence does not establish a temporalis-specific TN effect. [29,35] |
| Upper lip and infraorbital region | V2 skin, oral triggers and intraosseous dental branches | Superficial and submucosal case observations; a surface field is not complete maxillary dental coverage. [25–28] |
| Preauricular and parotid skin | Auriculotemporal and cervical sensory contributions | Surface location does not identify the gland as the analgesic target. [30,32] |
| Parotid gland | Glandular cholinergic secretion and salivary pain | Controlled sialorrhoea evidence and small first-bite series; no controlled TN gland study identified. [37,38] |
| Jawline and Nefertiti pattern | Platysma treatment crosses trigeminal and cervical surface territories | Aesthetic studies document regional effects; they do not establish comprehensive V3 coverage. [30,33,34,36] |
| Crow’s-feet region | Periocular skin versus orbicularis oculi muscle | Established aesthetic application; no controlled TN-specific lateral-canthal map identified. [4] |
| Forehead and frontalis | Predominantly V1 skin versus frontalis muscle | Aesthetic and migraine applications do not demonstrate remote mandibular or dental analgesia. [4,35] |
Regional descriptions distinguish skin or mucosa, muscle and gland. They summarize existing evidence rather than prescribe a unified treatment pattern.
References
- Headache Classification Committee of the International Headache Society. International Classification of Headache Disorders, third edition: 13.1.1 Trigeminal neuralgia. ICHD-3.
- Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. *Eur J Neurol.* 2019;26:831–849. doi:10.1111/ene.13950. Read source 2
- Royal College of Surgeons of England, Faculty of Dental Surgery. Guidelines for the management of trigeminal neuralgia. 2021. Guideline.
- AbbVie Ltd. BOTOX 100 Allergan Units: Summary of Product Characteristics. Electronic Medicines Compendium. Updated 15 May 2026; accessed 18 November 2026. Product information.
- Tereshko Y, Dal Bello S, Lettieri C, et al. Botulinum Toxin Type A for Trigeminal Neuralgia: A Comprehensive Literature Review. *Toxins.* 2024;16:500. doi:10.3390/toxins16110500.
- Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. *Cephalalgia.* 2012;32:443–450. doi:10.1177/0333102412441721.
- Zúñiga C, Piedimonte F, Díaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. *Clin Neuropharmacol.* 2013;36:146–150. doi:10.1097/WNF.0b013e31829cb60e.
- Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? *J Headache Pain.* 2013;14:92. doi:10.1186/1129-2377-14-92. Read source 8
- Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. *J Headache Pain.* 2014;15:65. doi:10.1186/1129-2377-15-65. Read source 9
- Zhang H, Lian Y, Xie N, Chen C, Zheng Y. Single-dose botulinum toxin type A compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study. *J Headache Pain.* 2017;18:81. doi:10.1186/s10194-017-0793-3.
- Hawa VP, Sardana V, Bhushan B, et al. Comparative Effect of Botulinum Toxin Therapy in Trigeminal Neuralgia With and Without Oral Medication: A Case Control Prospective Study. *NeuroQuantology.* 2025;23:120–128. doi:10.48047/nq.2025.23.10.nq25013. [DOI did not resolve during editorial checks; this citation and its findings remain unverified.]
- Li S, Lian YJ, Chen Y, et al. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. *J Headache Pain.* 2014;15:43. doi:10.1186/1129-2377-15-43.
- Zhang H, Lian Y, Xie N, et al. Factors affecting the therapeutic effect of botulinum toxin A on trigeminal neuralgia: a follow-up retrospective study of 152 patients. *Exp Ther Med.* 2019;18:3375–3382. doi:10.3892/etm.2019.7988.
- Asan F, Gündüz A, Tütüncü M, et al. Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA. *Headache.* 2022;62:1322–1328. doi:10.1111/head.14414.
- Tereshko Y, Valente M, Belgrado E, et al. The Therapeutic Effect of Botulinum Toxin Type A on Trigeminal Neuralgia: Are There Any Differences between Type 1 versus Type 2 Trigeminal Neuralgia? *Toxins.* 2023;15:654. doi:10.3390/toxins15110654.
- Xu YY, Guo CW, Chen HJ, et al. Efficacy of single vs. multiple botulinum toxin type A injections for trigeminal neuralgia. *Front Neurol.* 2025;16:1570447. doi:10.3389/fneur.2025.1570447.
- Santos RF, Machado M, Ferro M, Camões-Barbosa A. Botulinum Toxin Type A in Trigeminal Neuralgia Treatment: A Case Series and Literature Review. *Cureus.* 2024;16:e73389. doi:10.7759/cureus.73389.
- Liu J, Xu YY, Zhang QL, Luo WF. Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia. *Pain Res Manag.* 2018;2018:7365148. doi:10.1155/2018/7365148.
- Hosseini M, Asarzadegan F, Shafiee E, Alijanpour S. Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series). *Caspian J Intern Med.* 2023;14:376–379. doi:10.22088/cjim.14.2.376.
- Kqiku L, Weiglein AH, Pertl C, Biblekaj R, Städtler P. Histology and intramandibular course of the inferior alveolar nerve. *Clin Oral Investig.* 2011;15:1013–1016. doi:10.1007/s00784-010-0459-x.
- Nvabazam A, Judi R. Intraoral Botulinum Toxin Injection in Mental Foramen Site in the Treatment of Trigeminal Neuralgia. *J Evolution Med Dent Sci.* 2021;10:227–230. doi:10.14260/jemds/2021/49.
- Pearl C, Moxley B, Perry A, Demian N, Dallaire-Giroux C. Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases. *Dent J.* 2022;10:207. doi:10.3390/dj10110207.
- Wu C, Xie N, Liu H, Zhang H, Zhang L, Lian Y. A new target for the treatment of trigeminal neuralgia with botulinum toxin type A. *Neurol Sci.* 2018;39:599–602. doi:10.1007/s10072-017-3171-7.
- Jang Y. Ultrasound-Identified Trigger-Point and Ultrasound-Guided IncobotulinumtoxinA (Xeomin) Injection for Refractory V2-V3 Trigeminal Neuralgia: A Case Report. *Cureus.* 2025;17:e98146. doi:10.7759/cureus.98146.
- Radlberger RF, Leis S. A Case Report of Intraoral Injection of Botulinum Toxin A for Trigeminal Neuralgia: A Rare but Safe Intervention. *Cureus.* 2025;17:e80456. doi:10.7759/cureus.80456.
- Fida M, Alliu V, Filaj V, Sotiri I. Botulinum toxin type A treatment for Trigeminal Neuralgia: Case Report of a patient unresponsive to pharmacotherapy. *WDC Journal.* 2025;1:29–34. Primary article.
- Nguyen DC, et al. Anatomical Study of the Intraosseous Pathway of the Infraorbital Nerve. *J Craniofac Surg.* 2016;27:1094–1097. doi:10.1097/SCS.0000000000002619.
- Heasman PA. Clinical anatomy of the superior alveolar nerves. *Br J Oral Maxillofac Surg.* 1984;22:439–447. doi:10.1016/0266-4356(84)90051-290051-2).
- Yoshida K. Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia. *Toxins.* 2021;13:605. doi:10.3390/toxins13090605.
- Ella B, Langbour N, Caix P, Midy D, Deliac P, Burbaud P. Transverse cervical and great auricular nerve distribution in the mandibular area: a study in human cadavers. *Clin Anat.* 2015;28:109–117. doi:10.1002/ca.22369.
- Krag AE, Dumestre D, Hembd A, Glick S, Mohanty AJ, Rozen SM. Topographic and Neural Anatomy of the Depressor Anguli Oris Muscle and Implications for Treatment of Synkinetic Facial Paralysis. *Plast Reconstr Surg.* 2021;147:268e–278e. doi:10.1097/PRS.0000000000007593.
- Peuker ET, Filler TJ. The nerve supply of the human auricle. *Clin Anat.* 2002;15:35–37. doi:10.1002/ca.1089.
- Jabbour SF, Kechichian EG, Awaida CJ, Tomb RR, Nasr MW. Botulinum Toxin for Neck Rejuvenation: Assessing Efficacy and Redefining Patient Selection. *Plast Reconstr Surg.* 2017;140:9e–17e. doi:10.1097/PRS.0000000000003429.
- Awaida CJ, Jabbour SF, Rayess YA, et al. Evaluation of the Microbotox Technique: An Algorithmic Approach for Lower Face and Neck Rejuvenation and a Crossover Clinical Trial. *Plast Reconstr Surg.* 2018;142:640–649. doi:10.1097/PRS.0000000000004695.
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache.* 2010;50:921–936. doi:10.1111/j.1526-4610.2010.01678.x.
- Munoz-Lora VRM, Rogerio V, Roschel P, Zillo L, Cotofana S, Germani M. Injection Mapping and Dose Escalation for Botulinum Toxin Treatment on the Lower Face: A Randomized, Double-Blind Clinical Trial. *Aesthet Surg J.* 2026;sjag165. doi:10.1093/asj/sjag165.
- Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. *Neurology.* 2019;92:e1982–e1991. doi:10.1212/WNL.0000000000007368.
- Ghosh A, Mirza N. First bite syndrome: Our experience with intraparotid injections with botulinum toxin type A. *Laryngoscope.* 2016;126:104–107. doi:10.1002/lary.25571.
- Türk Börü Ü, Duman A, Bölük C, Coşkun Duman S, Taşdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up. *Medicine.* 2017;96:e8133. doi:10.1097/MD.0000000000008133.
- Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. *Headache.* 2019;59:1229–1239. doi:10.1111/head.13608.
- Yoshida K. Sphenopalatine Ganglion Block with Botulinum Neurotoxin for Treating Trigeminal Neuralgia Using CAD/CAM-Derived Injection Guide. *J Oral Facial Pain Headache.* 2020;34:135–140. doi:10.11607/ofph.2510.
- Thepsoparn M, Anukoolwittaya P, Toeypromthong P, Thanaboriboon C. Efficacy and safety profile of Onabotulinum toxin-A injection at sphenopalatine ganglion in trigeminal neuralgia: a prospective observational study. *J Headache Pain.* 2024;25:210. doi:10.1186/s10194-024-01926-9.
- Alebouyeh MR, Entezary SR, Salehi S, Saadat S. Efficacy of Botulinum Toxin Injection via Coronoid Approach in Refractory Trigeminal Neuralgia: A Case Report and Literature Review. *Pain Med Case Rep.* 2025;9:81–84. Primary article.
- Arce Galvez L, Mancera Alzate JM. Perineural botulinum toxin in the treatment of trigeminal traumatic neuropathic pain. *Cephalalgia Reports.* 2026;9. doi:10.1177/25158163251414012.
- Yao MH, Chen HC, Zhang XY, et al. Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. *J Headache Pain.* 2026;27:202. doi:10.1186/s10194-026-02454-4.
- Danysz W, Nunez-Badinez P, Gravius A, Fink K, Nagel J. Effects of IncobotulinumtoxinA in the Infraorbital Nerve Chronic Constriction Injury Model of Trigeminal Pain in Rats. *Biomedicines.* 2026;14:1175. doi:10.3390/biomedicines14051175.
- Rigshospitalet. Clinical trial of botulinum toxin A in trigeminal neuralgia. EUCT 2023-504567-17-00. Clinical Trials Information System.
- Stanford Medicine, Division of Pain Medicine. Botox for Trigeminal Neuralgia. Study information, accessed 18 November 2026. Institutional study page.

